http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111419853-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 |
| filingDate | 2020-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111419853-B |
| titleOfInvention | A combination of cucurbitacin and ibrutinib for treating breast cancer |
| abstract | The present invention relates to a pharmaceutical composition for treating breast cancer, especially triple-negative breast cancer, comprising cucurbitacin and ibrutinib. The invention also relates to the use of cucurbitacin combined with ibrutinib in preparing a medicine for treating triple-negative breast cancer. The combination of cucurbitacin and ibrutinib of the present invention has a significant synergistic effect on the treatment of breast cancer, especially triple-negative breast cancer, brings new hope for patients with such diseases, and at the same time provides a scientific basis and application prospect for the research and development of new tumor drugs wider. |
| priorityDate | 2020-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 73.